BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

743 related articles for article (PubMed ID: 18049333)

  • 1. Generation of EBV-specific T cells for adoptive immunotherapy: a novel protocol using formalin-fixed stimulator cells to increase biosafety.
    Hammer MH; Brestrich G; Mittenzweig A; Roemhild A; Zwinger S; Subklewe M; Beier C; Kurtz A; Babel N; Volk HD; Reinke P
    J Immunother; 2007; 30(8):817-24. PubMed ID: 18049333
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Generation of trispecific cytotoxic T cells recognizing cytomegalovirus, adenovirus, and Epstein-Barr virus: an approach for adoptive immunotherapy of multiple pathogens.
    Karlsson H; Brewin J; Kinnon C; Veys P; Amrolia PJ
    J Immunother; 2007; 30(5):544-56. PubMed ID: 17589295
    [TBL] [Abstract][Full Text] [Related]  

  • 3. T cell repertoire and Epstein-Barr virus-specific T cell response in chronic active Epstein-Barr virus infection: a case study.
    Gallot G; Hamidou MA; Clémenceau B; Gaschet J; Tiberghien P; Ferrand C; Vivien R; Barbarot S; Coste-Burel M; Moreau A; Vié H
    Clin Immunol; 2006 Apr; 119(1):79-86. PubMed ID: 16386957
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional CD4(+) and CD8(+) T-cell responses induced by autologous mitomycin C treated Epstein-Barr virus transformed lymphoblastoid cell lines.
    Meij P; Bloemena E; Palmen N; Brink A; Vervoort MB; Meijer CJ; Middeldorp JM
    Cell Immunol; 2001 Feb; 208(1):25-33. PubMed ID: 11277616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Virus-specific cytotoxic CD4+ T cells for the treatment of EBV-related tumors.
    Merlo A; Turrini R; Bobisse S; Zamarchi R; Alaggio R; Dolcetti R; Mautner J; Zanovello P; Amadori A; Rosato A
    J Immunol; 2010 May; 184(10):5895-902. PubMed ID: 20385879
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isolation and expansion of human adenovirus-specific CD4+ and CD8+ T cells according to IFN-gamma secretion for adjuvant immunotherapy.
    Feuchtinger T; Lang P; Hamprecht K; Schumm M; Greil J; Jahn G; Niethammer D; Einsele H
    Exp Hematol; 2004 Mar; 32(3):282-9. PubMed ID: 15003314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical grade generation of hexon-specific T cells for adoptive T-cell transfer as a treatment of adenovirus infection after allogeneic stem cell transplantation.
    Feuchtinger T; Richard C; Joachim S; Scheible MH; Schumm M; Hamprecht K; Martin D; Jahn G; Handgretinger R; Lang P
    J Immunother; 2008; 31(2):199-206. PubMed ID: 18481389
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sustained CD8+ T-cell immune response to a novel immunodominant HLA-B*0702-associated epitope derived from an Epstein-Barr virus helicase-primase-associated protein.
    Turcanová V; Höllsberg P
    J Med Virol; 2004 Apr; 72(4):635-45. PubMed ID: 14981767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of Epstein-Barr virus nuclear antigen 1, 3 and lytic antigen BZLF1 peptide pools allows fast and efficient stimulation of Epstein-Barr virus-specific T cells for adoptive immunotherapy.
    Wang Y; Aïssi-Rothe L; Virion JM; De Carvalho Bittencourt M; Ulas N; Audonnet S; Salmon A; Clement L; Venard V; Jeulin H; Stoltz JF; Decot V; Bensoussan D
    Cytotherapy; 2014 Jan; 16(1):122-34. PubMed ID: 24094498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recognition of Epstein-Barr virus-associated gastric carcinoma cells by cytotoxic T lymphocytes induced in vitro with autologous lymphoblastoid cell line and LMP2-derived, HLA-A24-restricted 9-mer peptide.
    Okugawa K; Itoh T; Kawashima I; Takesako K; Mazda O; Nukaya I; Yano Y; Yamamoto Y; Yamagishi H; Ueda Y
    Oncol Rep; 2004 Oct; 12(4):725-31. PubMed ID: 15375491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes.
    Comoli P; Pedrazzoli P; Maccario R; Basso S; Carminati O; Labirio M; Schiavo R; Secondino S; Frasson C; Perotti C; Moroni M; Locatelli F; Siena S
    J Clin Oncol; 2005 Dec; 23(35):8942-9. PubMed ID: 16204009
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dendritic cells expand Epstein Barr virus specific CD8+ T cell responses more efficiently than EBV transformed B cells.
    Subklewe M; Sebelin K; Block A; Meier A; Roukens A; Paludan C; Fonteneau JF; Steinman RM; Münz C
    Hum Immunol; 2005 Sep; 66(9):938-49. PubMed ID: 16360833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simultaneous generation of multivirus-specific and regulatory T cells for adoptive immunotherapy.
    Lugthart G; Albon SJ; Ricciardelli I; Kester MG; Meij P; Lankester AC; Amrolia PJ
    J Immunother; 2012 Jan; 35(1):42-53. PubMed ID: 22130159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HLA type-independent generation of antigen-specific T cells for adoptive immunotherapy.
    Hammer MH; Meyer S; Brestrich G; Moosmann A; Kern F; Tesfa L; Babel N; Mittenzweig A; Rooney CM; Hammerschmidt W; Volk HD; Reinke P
    Eur J Immunol; 2005 Jul; 35(7):2250-8. PubMed ID: 15915543
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Purification of melanoma reactive T cell by using a monocyte-based solid phase T-cell selection system for adoptive therapy.
    Li J; Mookerjee B; Wagner J
    J Immunother; 2008 Jan; 31(1):81-8. PubMed ID: 18157015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dendritic cells improve the generation of Epstein-Barr virus-specific cytotoxic T lymphocytes for the treatment of posttransplantation lymphoma.
    Wheatley GH; McKinnon KP; Iacobucci M; Mahon S; Gelber C; Lyerly HK
    Surgery; 1998 Aug; 124(2):171-6. PubMed ID: 9706135
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Establishment and characterization of Epstein-Barr virus-specific human CD4+ T lymphocyte clones.
    Honda S; Takasaki T; Okuno K; Yasutomi M; Kurane I
    Acta Virol; 1998 Nov; 42(5):307-13. PubMed ID: 10358731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epstein-Barr virus-specific cytotoxic T lymphocyte responses in the blood and tumor site of Hodgkin's disease patients: implications for a T-cell-based therapy.
    Chapman AL; Rickinson AB; Thomas WA; Jarrett RF; Crocker J; Lee SP
    Cancer Res; 2001 Aug; 61(16):6219-26. PubMed ID: 11507075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ex vivo generation of cytotoxic T lymphocytes specific for one or two distinct viruses for the prophylaxis of patients receiving an allogeneic bone marrow transplant.
    Regn S; Raffegerst S; Chen X; Schendel D; Kolb HJ; Roskrow M
    Bone Marrow Transplant; 2001 Jan; 27(1):53-64. PubMed ID: 11244438
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A sealed and unbreached system for purification, stimulation, and expansion of cytomegalovirus-specific human CD4 and CD8 T lymphocytes.
    Li Pira G; Bottone L; Ivaldi F; Pelizzoli R; Risso M; Tripodi G; Manca F
    Transfusion; 2006 Dec; 46(12):2053-62. PubMed ID: 17176316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.